2 weeks Ago By Defense World Staff
Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) – Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Daré Bioscience in a research report issued on Tuesday, April 1st. HC Wainwright analyst D.
Tsao anticipates that the biotechnology company will post earnings per share of $15.48 for the year. HC Wainwright has a “Buy” rating and a $12.
00 price target on the stock. The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share.
Daré Bioscience Stock Up 0.7 %NASDAQ DARE opened at $2.93 on Thursday.
Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56.
The firm has a market capitalization of $25.49 million, a price-to-earnings ratio of -4.96 and a beta of 1.
38. The company has a fifty day moving average of $3.04 and a two-hundred day moving average of $3.
28. Daré Bioscience (NASDAQ:DARE – Get Free Report) last announced its earnings results on Monday, March 31st. The biotechnology company reported ($0.
64) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.
The company had revenue of ($0.06) million during the quarter, compared to analysts’ expectations of $1.00 million.
Institutional Investors Weigh In On Daré BioscienceSeveral institutional investors have recently made changes to their positions in DARE. AMH Equity Ltd raised its position in Daré Bioscience by 50.0% in the 4th quarter.
AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the period. Jane Street Group LLC bought a new position in shares of Daré Bioscience during the fourth quarter valued at approximately $52,000. Renaissance Technologies LLC raised its holdings in shares of Daré Bioscience by 6.
7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after buying an additional 4,300 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Daré Bioscience by 4.
0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 3,593 shares during the last quarter. Institutional investors own 6.
70% of the company’s stock. Daré Bioscience Company Profile (Get Free Report)Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.Featured StoriesFive stocks we like better than Daré Bioscience3 Stocks to Protect Your Portfolio from the Coronavirus Contagion Shares of RH Down Nearly 40%: Where Investors Can Turn To NowWhat is the Nasdaq? Complete Overview with HistoryTariffs, Spin-Out, and R2 Updates Are Positive Signs for RivianHow to Invest in Blue Chip StocksCathie Wood Loads Up on Baidu—Is It the Right Time to Buy?.
_0.jpg?itok=yAIF6nFK)
